

Figure 1



Figure 2



Figure 3



Figure 4


PD-1
CD28
CTLA4
ICOS
BTLA
PD-L1
PD-L2
CD80
CD86
B7-H2
OD450nm
2.5
2.0
1.5
1.0
0.5
0.0
chimeric monoclonal antibody
pembrolizumab
isotype control

Figure 5


PD-1/PD-L1 Blocking Activity
pembrolizumab, IC50=1.045nM
chimeric antibody, IC50=0.972nM
OD450nm
Concentration(nM)
PD-1/PD-L2 Blocking Activity
pembrolizumab, IC50=0.888nM
chimeric antibody, IC50=0.895nM
OD450nm
Concentration(nM)

Figure 6


Naive
Vehicle
pembrolizumab
chimeric monoclonal antibody
IL-2 (pg/mL)
200
150
100
50
0
0.03
0.3
3
30
300
Concentration(nM)
IFN-γ (pg/mL)
6000
4000
2000
0
Concentration(nM)

Figure 7



Figure 8



Figure 9